Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine if a reduction in the enzyme 1-hydroxylase, which activates Vitamin D, is the cause of overactivity of the parathyroid glands (called secondary hyperparathyroidism - normal blood calcium and elevated parathyroid hormone) in a selected group of young patients with normal kidney function.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Maryland; University of Maryland, Baltimore
• Treatments: Ergocalciferols; Teriparatide; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Caucasian female

• Age 40-59 years

• Serum creatinine < 1.3 and estimated glomerular filtration rate (GRF) > 60

• Serum calcium in the normal range (for U Md lab 8.6-10 mg/dl)

• Parathyroid hormone in the normal range (for U Md lab 12-54 pg/ml)

• Normal 25-hydroxyvitamin D level (30 ng/ml or higher)

• For women of childbearing age, non-pregnant (based on negative urine pregnancy test on the morning of the teriparatide infusion)

Exclusion Criteria:

• Non-caucasian

• Age under 40 and over 59 years

• Male

• Serum creatinine over 1.3 or estimated glomerular filtration rate (GFR) < 60

• Abnormal serum calcium (for U Md lab, below 8.6 or above 10 mg/dl)

• Abnormal parathyroid hormone (for U Md lab, above 65 or below 12 pg/ml)

• For women of childbearing age, non-pregnant (based on urine pregnancy test on the morning of the teriparatide infusion)

• History of bone radiation

• History of Paget disease of bone

• History of bone malignancy or metastases

• History of allergy or sensitivity to Forteo